recent
data
center
diseas
control
cdc
estim
human
noroviru
nov
respons
million
total
case
ill
annual
caus
nonbacteri
gastroenter
report
year
human
nov
highli
infecti
resist
common
disinfect
caus
debilit
ill
reason
viru
consid
categori
b
biodefens
agent
nation
institut
allergi
infecti
diseas
recent
year
import
virus
caus
foodborn
diseas
increasingli
appreci
virus
commonli
associ
foodborn
diseas
human
nov
import
estim
account
foodborn
ill
report
everi
year
base
data
avail
million
case
foodrel
ill
caus
human
nov
estim
occur
year
lead
hospit
nearli
death
estim
annual
cost
human
nov
foodborn
diseas
base
hospit
lost
wage
reach
nearli
billion
us
dollar
despit
consider
impact
human
nov
public
health
approv
antivir
drug
vaccin
combat
viru
human
nov
caus
sever
gastroenter
character
vomit
diarrhea
stomach
cramp
vomit
seen
commonli
infant
children
wherea
adult
usual
present
diarrhea
diarrhea
associ
diseas
free
blood
mucu
leukocyt
characterist
differenti
novassoci
diarrhea
diarrhea
caus
bacteri
pathogen
e
coli
blood
appear
stool
incub
period
diseas
usual
hour
durat
diseas
hour
nov
affect
peopl
age
usual
requir
hospit
howev
sever
diseas
may
observ
infant
children
elderli
immunocompromis
individu
may
requir
support
care
immunocompromis
patient
chronic
nov
infect
document
lead
increas
morbid
mortal
compar
gener
popul
nov
outbreak
seem
clear
season
case
report
winter
month
infect
individu
may
shed
viru
stool
day
titer
high
genom
copi
per
gram
stool
human
nov
highli
stabl
environ
resist
common
disinfect
alcoholbas
sanit
phenol
compound
propag
diseas
point
sourc
outbreak
commonli
occur
first
document
human
nov
outbreak
occur
town
norwalk
ohio
viru
offici
identifi
use
immun
electron
microscopi
effect
measur
control
human
nov
commonli
use
sanit
effect
human
nov
highpressur
process
promis
inactiv
human
nov
food
vaccin
antivir
drug
human
nov
approv
us
food
drug
administr
human
nov
vlpbase
vaccin
live
vector
vaccin
develop
test
anim
model
human
clinic
trial
iem
human
nov
commonli
call
stomach
flu
winter
vomit
diseas
symptom
increas
diseas
occurr
winter
month
human
nov
member
genu
noroviru
within
famili
calicivirida
noroviru
genu
subdivid
genogroup
gi
gv
gi
gii
giv
caus
human
diseas
giii
bovin
nov
gv
includ
murin
nov
genogroup
divid
genotyp
least
genotyp
assign
gii
genogroup
alon
preval
human
nov
strain
circul
human
popul
belong
genogroup
ii
genotyp
past
year
global
pandem
occur
caus
strain
gii
new
orlean
strain
identifi
winter
preval
strain
identifi
outbreak
unit
state
displac
minerva
strain
recent
new
emerg
strain
identifi
sydney
strain
account
half
human
nov
outbreak
report
septemb
decemb
long
debat
whether
longterm
immun
acquir
human
nov
infect
data
limit
volunt
studi
involv
human
nov
strain
believ
divers
strain
human
nov
play
integr
part
evas
immun
system
even
close
relat
strain
human
nov
show
major
antigen
receptor
bind
differ
host
suscept
also
play
import
role
human
nov
infect
earli
volunt
studi
human
nov
strain
found
individu
show
symptom
diseas
exposur
viru
recent
studi
shown
individu
blood
type
suscept
strain
infect
peopl
blood
type
human
nov
use
histoblood
group
antigen
hbga
famili
glycan
found
mani
cell
type
function
receptor
hgba
found
erythrocyt
epitheli
cell
well
bodi
secret
saliva
breast
milk
differ
strain
human
nov
may
differ
bind
affin
differ
hbga
includ
b
h
lewi
antigen
fucosyl
transferas
gene
determin
individu
statu
either
secretor
nonsecretor
individu
allel
alon
consid
nonsecretor
wherea
individu
allel
consid
secretor
gene
encod
lewi
enzym
add
fucos
either
linkag
hbga
precursor
disaccharid
lead
synthesi
trisaccharid
requir
lewi
phenotyp
lewi
phenotyp
also
refer
nonsecretor
phenotyp
gene
encod
fucosyltransferas
add
fucos
linkag
precursor
creat
h
type
antigen
glycosyl
lewi
b
enzym
occur
lead
express
hbga
secretor
phenotyp
individu
blood
type
secretornonsecretor
statu
shown
play
role
suscept
infect
particular
human
nov
strain
electron
microscopi
em
human
nov
look
like
small
round
particl
rang
nm
diamet
nonenvelop
viru
outer
shell
viru
particl
highli
stabl
protein
capsid
carri
shallow
cuplik
circular
indent
show
icosahedr
symmetri
insid
capsid
genet
materi
singlestrand
positivesens
rna
genom
genom
human
nov
approxim
kb
long
divid
open
read
frame
orf
encod
nonstructur
polyprotein
encod
major
capsid
protein
encod
minor
capsid
protein
polyprotein
encod
proteolyt
cleav
nonstructur
protein
order
nucleosidetriphosphatas
vpg
pro
rna
depend
rna
polymeras
rdrp
function
mani
protein
deciph
homolog
found
cultiv
surrog
virus
murin
nov
felin
caliciviru
replic
gene
express
viru
produc
subgenom
rna
encod
viral
encod
protein
vpg
coval
link
end
human
nov
genom
subgenom
rna
function
vpg
may
involv
initi
viral
protein
translat
recruit
translat
machineri
capsid
human
nov
made
dimer
major
capsid
protein
copi
minor
capsid
protein
compos
amino
acid
molecular
weight
rang
kda
express
protein
alon
form
empti
noninfecti
viruslik
particl
vlp
antigen
morpholog
similar
nativ
human
nov
virion
vital
determin
antigen
receptor
bind
activ
immunogen
strain
specif
classif
nov
genogroup
genotyp
fold
form
domain
shell
protrus
p
link
flexibl
hing
region
fig
domain
involv
format
continu
shell
surfac
p
domain
form
promin
protrus
eman
shell
p
domain
divid
subdomain
see
fig
p
domain
primari
site
antibodi
recognit
receptor
bind
play
import
role
human
nov
infect
determin
host
suscept
studi
human
nov
hinder
absenc
cell
cultur
system
lack
small
anim
model
therefor
mani
aspect
human
nov
molecular
biolog
gene
express
replic
pathogenesi
immunolog
poorli
understood
surviv
human
nov
effect
measur
inactiv
human
nov
accur
evalu
human
nov
grown
cell
cultur
laboratori
effort
studi
viru
use
cultiv
surrog
surrog
includ
virus
close
relat
human
nov
term
genet
makeup
size
receptor
bind
pathogen
environment
stabil
exampl
surrog
virus
includ
murin
nov
felin
caliciviru
porcin
sapoviru
tulan
viru
major
disadvantag
use
murin
nov
felin
caliciviru
surrog
virus
caus
gastroenter
murin
nov
caus
system
infect
mice
wherea
felin
caliciviru
caus
respiratori
tract
infect
cat
propos
porcin
sapoviru
tulan
viru
may
better
surrog
caus
symptom
gastroenter
anim
particularli
tulan
viru
recogn
type
b
hbga
similar
human
nov
surrog
use
studi
human
nov
includ
vlp
p
domain
particl
pparticl
particl
resembl
portion
human
nov
protein
capsid
import
receptor
bind
viru
host
cell
antigen
recognit
viru
immun
system
particl
noninfecti
compos
protein
lack
viral
genom
compon
nativ
viru
although
use
surrog
aid
understand
human
nov
limit
compar
data
gener
use
surrog
human
nov
mode
transmiss
human
nov
typic
fecalor
rout
direct
transmiss
person
person
howev
indirect
transmiss
occur
contamin
food
water
surfac
fomit
also
evid
direct
transmiss
via
aerosol
vomitu
infecti
dose
human
nov
low
usual
report
fewer
viral
particl
recent
public
base
human
volunt
studi
mathemat
model
estim
high
risk
infect
caus
exposur
human
nov
particl
human
nov
shed
stool
infect
individu
viral
shed
peak
day
infect
viral
shed
typic
last
day
immunocompet
individu
howev
immunocompromis
individu
viral
shed
report
day
infect
chronic
case
viral
shed
occur
year
viral
copi
per
gram
fece
typic
shed
infect
individu
approxim
onethird
human
novinfect
individu
asymptomat
activ
shed
viru
lead
propag
diseas
mention
previous
immunocompromis
patient
human
nov
infect
sever
even
chronic
increas
durat
nov
ill
document
immunosuppress
patient
result
congenit
immunodefici
chemotherapi
immunosuppress
therapi
human
immunodefici
viru
hiv
infect
complic
human
nov
infect
immunocompromis
includ
dehydr
malnutrit
dysfunct
intestin
barrier
contribut
higher
mortal
observ
individu
viral
shed
also
increas
patient
last
week
year
addit
contrast
gener
popul
normal
infect
stabl
variant
human
nov
clinic
sampl
immunocompromis
patient
test
posit
array
human
nov
variant
normal
observ
healthi
individu
patient
proper
hand
hygien
use
limit
human
nov
exposur
well
isol
visitor
staff
show
symptom
gastroenter
outbreak
human
nov
popular
lay
press
associ
cruis
ship
occur
area
peopl
close
contact
human
nov
outbreak
report
restaur
retir
commun
school
hospit
nurs
home
hotel
stadia
militari
instal
recent
outbreak
data
cdc
indic
half
confirm
outbreak
human
nov
occur
longterm
care
facil
confirm
outbreak
attribut
longterm
care
facil
trace
restaur
sourc
parti
event
hospit
school
cruis
ship
unknown
sourc
high
densiti
individu
set
pair
fact
food
consum
locat
normal
prepar
other
contribut
high
instanc
human
nov
outbreak
locat
human
nov
highli
stabl
environ
make
difficult
erad
primari
infect
occur
estim
stool
individu
activ
nov
infect
may
shed
billion
viru
particl
per
gram
fece
fact
pair
low
infecti
dose
human
nov
account
rapid
spread
viru
close
commun
result
poor
hygien
approxim
human
nov
infect
asymptomat
consequ
asymptomat
carrier
pass
human
nov
peopl
food
handl
human
nov
foodborn
diseas
commonli
associ
food
undergo
littl
process
consumpt
fresh
produc
raw
shellfish
prepar
food
food
handler
unknowingli
transfer
viru
prepar
human
nov
outbreak
associ
mani
type
food
includ
fresh
cut
fruit
lettuc
tomato
melon
salad
green
onion
strawberri
blueberri
raspberri
salsa
oyster
clam
shellfish
confirm
nov
foodborn
outbreak
could
trace
singl
food
commod
leafi
veget
contribut
outbreak
fruitsnut
associ
outbreak
mollusk
respons
outbreak
howev
complex
food
implic
outbreak
wherea
attribut
simpl
food
evid
suggest
food
may
becom
contamin
poor
hygien
food
handler
viral
contamin
occur
upstream
food
product
process
outbreak
human
nov
associ
raspberri
link
sewag
irrig
water
outbreak
human
nov
also
associ
oyster
grown
water
contamin
human
wast
henc
prevent
measur
product
process
handl
prepar
consid
help
minim
human
nov
contamin
step
farm
fork
investig
human
nov
outbreak
complic
outbreak
associ
food
water
fomit
persontoperson
contact
present
tabl
show
mani
way
viru
transmit
determin
human
nov
caus
outbreak
often
hamper
limit
mode
detect
viru
genet
divers
found
within
genu
noroviru
determin
human
nov
caus
outbreak
often
determin
combin
symptomatolog
exclus
enter
pathogen
culprit
howev
import
advanc
surveil
human
nov
outbreak
made
recent
year
march
calicinet
outbreak
surveil
network
human
nov
launch
cdc
partner
state
health
depart
calicinet
particip
electron
enter
epidemiolog
sequenc
data
nov
outbreak
allow
link
multist
common
sourc
outbreak
identif
emerg
viru
strain
local
state
health
depart
certifi
upload
laboratori
result
calicinet
enhanc
capac
health
depart
test
human
nov
databas
epidemiolog
data
undoubtedli
improv
accuraci
efficaci
outbreak
investig
winter
calicinet
identifi
emerg
preval
strain
human
nov
circul
unit
state
new
orlean
strain
januari
cdc
releas
calicinet
surveil
data
septemb
decemb
indic
new
predomin
human
nov
strain
circul
unit
state
sydney
strain
displac
new
orlean
strain
human
nov
variant
account
total
outbreak
period
remain
outbreak
caus
gi
gii
strain
outbreak
associ
sydney
unit
state
transmit
direct
persontoperson
contact
foodborn
waterborn
transmit
unknown
rout
previou
season
peak
human
nov
outbreak
month
januari
impact
morbid
mortal
sydney
strain
may
fulli
understood
threshold
sydney
strain
first
identifi
australia
march
correl
increas
outbreak
europ
japan
compar
previou
season
new
variant
emerg
everi
year
sinc
believ
caus
popul
immun
genet
drift
clinic
diagnosi
human
nov
infect
usual
base
symptom
acut
onset
vomit
wateri
nonbloodi
diarrhea
abdomin
cramp
nausea
lowgrad
fever
headach
howev
confirm
caus
must
reli
laboratori
diagnost
tool
particularli
mani
human
nov
infect
asymptomat
human
nov
grown
cell
cultur
viral
rna
viral
protein
viral
particl
target
detect
limit
nov
detect
low
concentr
virus
sampl
extrem
genet
antigen
divers
seen
within
genu
noroviru
crossreact
antibodi
detect
circul
strain
use
enzym
immunoassay
eia
likewis
nucleic
acid
detect
assay
also
hamper
low
sequenc
homolog
genet
divers
thu
singl
primer
pair
insuffici
detect
nov
strain
yet
free
falseposit
reaction
viral
particl
detect
em
iem
solidphas
iem
spiem
expens
requir
highli
train
observ
distinguish
nov
enter
virus
larg
number
outbreak
specimen
rapidli
examin
detect
human
nov
implic
food
complic
complex
food
matrix
low
level
virus
gener
determin
foodborn
outbreak
associ
human
nov
reli
epidemiolog
investig
laboratori
test
viru
must
isol
peopl
becom
ill
consumpt
food
item
sometim
outbreak
may
trace
food
handler
also
harbor
human
nov
recent
trend
food
microbiolog
focu
virus
certainli
lead
improv
molecular
detect
method
human
nov
food
summari
detect
method
found
tabl
initi
rna
detect
method
nov
reversetranscriptas
polymeras
chain
reaction
rtpcr
assay
rt
quantit
pcr
rtqpcr
assay
consid
gold
standard
nov
detect
use
mani
public
health
clinic
food
environment
research
laboratori
addit
rtpcr
rtqpcr
amplif
variat
rt
multiplex
pcr
rtnest
pcr
direct
rtpcr
rtnest
realtim
pcr
rtbooster
pcr
nucleic
acid
sequencebas
amplif
use
detect
nov
variou
specimen
recent
revers
transcript
loopmedi
isotherm
amplif
approach
also
use
rapid
detect
nov
probabl
detect
nov
caus
outbreak
least
sampl
patient
need
test
use
standard
rtpcr
assay
nov
molecular
detect
method
like
rtqpcr
alway
costeffect
adapt
health
care
set
eg
physician
offic
local
health
depart
small
laboratori
offsit
clinic
nurs
home
field
site
commerci
eia
develop
test
human
specimen
immunolog
detect
nov
shown
limit
applic
earlygener
eiasenzymelink
immunosorb
assay
elisa
review
eiaelisa
studi
indic
sensit
nov
detect
rang
specif
rang
evalu
thirdgener
eia
shown
vast
improv
sensit
specif
consequ
commerci
eia
kit
offer
improv
rapid
diagnosi
sporad
infect
also
applic
outbreak
screen
probabl
detect
nov
caus
outbreak
minimum
specimen
patient
test
use
earliergener
elisa
immunochromatograph
icg
assay
develop
could
help
especi
screen
specimen
sporad
outbreak
case
addit
simpl
sensit
specif
rapid
inexpens
pointofcar
test
poct
would
help
medic
public
health
asset
best
poct
nov
icg
assay
poct
kit
human
nov
potenti
improv
sensit
specif
result
recent
develop
fluoresc
immunochromatographi
human
nov
detect
em
procedur
although
direct
em
limit
sensit
outbreak
human
nov
suspect
caus
molecular
detect
result
repeatedli
neg
human
nov
patient
specimen
examin
direct
em
potenti
viral
pathogen
low
specif
mani
human
nov
molecular
assay
correct
diagnosi
may
miss
techniqu
direct
em
would
elucid
human
nov
caus
also
nonspecifi
viral
agent
may
identifi
use
direct
em
may
detect
clinic
laboratori
assay
mani
diagnost
laboratori
may
capac
direct
em
analysi
virus
caus
gastroenter
partner
public
health
system
would
requir
type
identif
addit
pool
outbreak
specimen
concentr
specimen
pool
would
speed
detect
caus
potenti
caus
detect
pool
time
taken
examin
individu
specimen
agent
match
agent
found
concentr
pool
difficult
predict
futur
trend
detect
human
nov
howev
high
probabl
current
rtqpcr
approach
detect
nov
clinic
specimen
modifi
use
nanoparticl
probe
nucleic
acid
multiplex
test
base
nanospher
microarray
technolog
alreadi
avail
detect
respiratori
virus
complet
process
sampl
final
result
take
approxim
hour
technolog
feasibl
detect
clinic
specimen
wide
varieti
nov
genogroup
genotyp
new
genet
variant
specimen
realtim
basi
futur
bright
rapid
accur
pointofcar
detect
nov
human
nov
high
environment
stabil
low
infecti
dose
make
control
transmiss
viru
challeng
cdc
publish
guidelin
disinfect
procedur
human
nov
outbreak
recommend
disinfect
surfac
disinfect
ppm
household
bleach
sodium
hypochlorit
howev
human
nov
cultiv
efficaci
treatment
disinfect
approv
us
environment
protect
agenc
human
nov
establish
use
surrog
virus
surrog
virus
may
accur
repres
disinfect
kinet
human
nov
remain
suitabl
represent
cdc
recommend
increas
clean
ward
twice
daili
contact
surfac
time
daili
ppm
chlorin
epaapprov
disinfect
human
nov
outbreak
increas
efficaci
decontamin
summari
current
data
efficaci
sanit
human
nov
clinic
isol
found
tabl
data
reli
sole
rtqpcr
assess
genom
rna
copi
howev
method
coupl
genom
rna
detect
human
nov
bind
abil
hbga
recent
use
accur
determin
viral
inactiv
although
sanit
use
human
novcontamin
surfac
approv
food
use
accord
us
food
drug
administr
fda
sodium
hypochlorit
concentr
less
ppm
may
use
food
sanit
purpos
fda
cfr
concentr
chlorin
effect
log
viru
reduct
remov
viral
contamin
food
matrix
organ
materi
also
affect
abil
sanit
inact
virus
thermal
treatment
effect
mean
inactiv
pathogen
howev
appropri
valu
temperatur
time
requir
elimin
log
pathogen
establish
human
nov
recent
data
thermal
inactiv
human
nov
present
tabl
howev
highestrisk
food
human
nov
contamin
fresh
produc
shellfish
normal
minim
process
eaten
raw
mildli
heat
sever
nontherm
process
option
exist
treatment
fresh
produc
shellfish
includ
highpressur
process
hpp
g
irradi
ultraviolet
irradi
ozon
puls
electr
field
mani
technolog
evalu
efficaci
human
nov
use
surrog
murin
nov
felin
caliciviru
research
nontherm
process
human
nov
clinic
isol
summar
tabl
promis
human
nov
inactiv
technolog
seem
hpp
human
novinocul
oyster
treat
mpa
minut
subsequ
fed
human
volunt
oyster
caus
infect
human
indic
viru
inactiv
similarli
pressur
mpa
minut
could
inhibit
bind
human
nov
vlp
hbga
receptor
anoth
studi
use
highpressur
treatment
mpa
minut
treat
nov
isol
significantli
decreas
abil
viru
bind
hbga
receptor
studi
hpp
promis
howev
research
use
human
nov
isol
requir
substanti
find
well
appropri
evalu
nontherm
process
viral
inactiv
vaccin
effect
strategi
protect
human
infecti
diseas
fdaapprov
vaccin
human
nov
although
human
nov
caus
selflimit
ill
caus
signific
health
econom
emot
burden
recent
epidemiolog
studi
found
sever
clinic
outcom
includ
death
often
associ
highrisk
popul
elderli
children
immunocompromis
individu
cdc
estim
clinic
visit
children
develop
world
occur
annual
result
nov
infect
lead
estim
hospit
human
nov
caus
averag
death
per
year
unit
state
howev
estim
reduc
recent
year
mortal
novassoci
infect
increas
epidem
season
burden
human
nov
greater
develop
thermal
process
gaseou
ozon
log
reduct
nov
rna
surfac
hudson
et
al
world
cdc
estim
nov
caus
death
children
younger
year
everi
year
develop
countri
effect
vaccin
would
highli
benefici
increas
clinic
signific
human
nov
infect
suggest
urgent
need
efficaci
vaccin
human
nov
particularli
popul
high
risk
food
handler
militari
personnel
elderli
infant
children
immunocompromis
individu
effect
vaccin
would
prevent
acut
gastroenter
caus
viru
also
block
transmiss
rout
thu
improv
food
safeti
public
health
biodefens
human
nov
cultiv
vaccin
studi
focus
subunit
vaccin
use
antigen
protein
express
mani
express
system
includ
yeast
escherichia
coli
insect
cell
mammalian
cell
line
tobacco
potato
express
system
selfassembl
vlp
structur
antigen
similar
nativ
virion
vlp
contain
optim
epitop
trigger
human
novspecif
immun
respons
host
baculovirusinsect
cell
express
system
shown
effici
express
system
vlp
mice
immun
vlpbase
vaccin
candid
stimul
variabl
level
antibodi
tcell
intestin
vagin
mucos
immun
depend
vaccin
dosag
rout
type
adjuv
howev
known
whether
immun
protect
mice
suscept
human
nov
infect
recent
found
gnotobiot
pig
inocul
human
nov
develop
symptom
gastroenter
includ
mild
diarrhea
viral
shed
fece
patholog
chang
small
intestin
subsequ
found
gnotobiot
pig
vaccin
vlp
mucos
adjuv
immunostimul
complex
iscom
mutant
e
coli
lt
toxin
mlt
trigger
novspecif
antibodi
respons
thyroxin
th
th
serum
cytokin
cytokinesecret
cell
mucos
immun
respons
vaccin
candid
induc
increas
protect
rate
viral
shed
diarrhea
compar
unvaccin
control
data
suggest
vlpbase
vaccin
protect
gnotobiot
pig
vlpbase
vaccin
candid
test
human
clinic
trial
tabl
ball
colleagu
perform
first
clinic
studi
show
baculovirusexpress
human
nov
vlp
safe
immunogen
human
administ
oral
elkamari
colleagu
tacket
colleagu
perform
human
volunt
studi
use
norwalk
vlp
antigen
thirtysix
healthi
adult
volunt
receiv
mg
n
mg
n
mg
n
oral
administ
vlp
without
adjuv
placebo
n
vaccine
develop
signific
increas
iga
antivlp
antibodysecret
cell
nineti
percent
receiv
mg
develop
increas
serum
antivlp
igg
howev
neither
rate
seroconvers
antibodi
titer
increas
higher
vaccin
dose
later
effect
vlp
contain
chitosan
vaccin
dose
immun
respons
compar
human
volunt
individu
develop
serum
igg
individu
develop
serum
iga
receiv
mg
vlp
rate
igg
iga
increas
respect
vaccin
dose
increas
mg
although
studi
show
vlpbase
vaccin
candid
safe
immunogen
determin
whether
protect
human
human
novinduc
gastroenter
recent
human
studi
conduct
healthi
adult
assess
protect
efficaci
vlp
vaccin
candid
chitosan
monophosphoryl
lipid
mpl
adjuv
tabl
advantag
vlpbase
vaccin
candid
safe
immunogen
human
howev
durat
immun
respons
may
limit
vlp
nonrepl
protein
unknown
whether
provid
crossprotect
heterogen
strain
human
nov
howev
discuss
earlier
longterm
immun
acquir
human
nov
infect
strain
divers
crossprotect
heterogen
strain
unlik
exampl
chimpanze
vaccin
vlp
deriv
strain
fail
protect
norwalk
viru
strain
provid
evid
vlp
may
provid
crossprotect
differ
genotyp
nov
addit
product
vlp
vitro
time
consum
expens
immun
usual
requir
high
dosag
vlp
multipl
booster
immun
efficaci
vlpbase
vaccin
reli
addit
mucos
adjuv
cholera
toxin
e
coli
toxin
iscom
chitosan
mpl
first
liveviru
vector
vaccin
report
smith
colleagu
recombin
vaccinia
viru
express
hepat
b
surfac
antigeninduc
hepat
bspecif
antibodi
rabbit
discoveri
inspir
develop
mani
liveviru
vector
dna
virus
adenovirus
herpesvirus
positivestrand
rna
virus
alphavirus
flavivirus
negativesens
rna
virus
vesicular
stomat
viru
vsv
newcastl
diseas
viru
gener
live
vector
vaccin
may
suitabl
follow
condit
virus
caus
persist
infect
hiv
hepat
c
viru
hcv
virus
highli
lethal
sever
acut
respiratori
syndrom
ebola
marburg
virus
virus
grown
cell
cultur
human
nov
three
live
vector
vaccin
candid
develop
human
nov
harrington
colleagu
first
develop
venezuelan
equin
enceph
vee
vector
human
nov
vaccin
candid
vee
replicon
express
norwalk
vlp
induc
system
mucos
heterotyp
immun
nov
recent
adenoviru
express
capsid
protein
human
nov
construct
mice
vaccin
adenovirusvector
human
nov
vaccin
produc
system
mucos
cellular
th
th
immun
respons
combin
adenovirusvector
vaccin
vlpbase
subunit
vaccin
enhanc
human
novspecif
immun
recent
li
gener
recombin
vsv
vector
human
nov
vaccin
candid
mice
inocul
singl
dose
pfu
intranas
oral
rout
stimul
significantli
stronger
humor
cellular
immun
respons
baculovirusexpress
vlp
vaccin
furthermor
recombin
trigger
strong
human
novspecif
immun
gnotobiot
piglet
protect
pig
challeng
human
nov
strain
show
live
vector
human
nov
vaccin
protect
anim
model
although
live
vector
vaccin
candid
promis
may
challeng
implement
use
human
clinic
trial
exampl
biosafeti
vee
may
issu
vee
biodefens
pathogen
use
function
vee
gene
restrict
deliveri
adenovirusvector
vaccin
may
hamper
larg
portion
global
popul
preexist
immun
adenoviru
vector
although
vsv
human
pathogen
littl
experi
vsv
administr
human
least
independ
phase
human
clinic
trial
perform
test
safeti
immun
respons
effect
vsvbase
hiv
vaccin
oncolyt
therapi
human
seem
clear
detail
inform
safeti
efficaci
vsvbase
vaccin
human
forthcom
outcom
studi
facilit
futur
clinic
trial
vsv
vector
nov
vaccin
candid
human
human
nov
number
caus
foodborn
ill
despit
research
effort
human
nov
still
poorli
understood
understudi
effect
measur
elimin
viru
food
environ
futur
research
effort
focu
develop
effici
cell
cultur
system
small
anim
model
rapid
sensit
detect
method
novel
sanit
control
intervent
vaccin
antivir
drug
furthermor
urgent
need
build
multidisciplinari
multiinstitut
team
combat
import
biodefens
agent
